Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTBK1 | Q5TCY1 | 2/20 | 0.58 |
| ▸ | TTBK2 | Q6IQ55 | 2/20 | 0.58 |
| ▸ | KDR | P35968 | 2/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.48 |
| ▸ | MET | P08581 | 11/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.47 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29631643 | 1.00 | TTBK1 (0.58) | TTBK1TTBK2KDRPDGFRAMET | |
| SCHEMBL4364193 | 0.83 | MET (0.45) | TTBK1TTBK2KDRMETBRAF | |
| SCHEMBL1895723 | 0.82 | PDGFRA (0.47) | TTBK1TTBK2KDRPDGFRAHSPB1 | |
| SCHEMBL30844464 | 0.81 | KMT2A (0.52) | TTBK1TTBK2MET | |
| SCHEMBL4249568 | 0.81 | MET (0.55) | METHSPB1 | |
| SCHEMBL29631514 | 0.81 | MET (0.55) | METHSPB1 | |
| SCHEMBL3484554 | 0.81 | KMT2A (0.52) | TTBK1TTBK2MET | |
| SCHEMBL4361630 | 0.80 | MET (0.45) | TTBK1TTBK2KDRMETBRAF | |
| SCHEMBL30310261 | 0.80 | PDGFRA (0.47) | TTBK1TTBK2KDRPDGFRAHSPB1 | |
| SCHEMBL26084095 | 0.80 | PDGFRA (0.47) | TTBK1TTBK2KDRPDGFRAHSPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110520416-B | Polysubstituted pyridone derivative, preparation method and medical application thereof | 北京越之康泰生物医药科技有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-112047941-B | Compound and application thereof in preparing medicine for treating diseases caused by high expression of Flt3/c-Met kinase | 温州医科大学 | 2021-10-29 | — | — | CN | disclosed |
| CN-112047941-A | Compound and application thereof in preparing medicine for treating diseases caused by high expression of Flt3/c-Met kinase | 温州医科大学 | 2020-12-08 | — | — | CN | disclosed |
| CN-110520416-A | Polysubstituted pyridine ketones derivant, preparation method and its medical usage | BEIJING YUEZHIKANGTAI BIOMEDICINES CO LTD | 2019-11-29 | — | — | CN | disclosed |
| CN-106810549-B | 7- azaindoles and its application containing dihydrogen dazin structure | 江西科技师范大学 | 2019-05-24 | — | — | CN | disclosed |
| US-8372981-B2 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-02-12 | — | — | US | disclosed |
| US-8372981-B2 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-02-12 | — | — | US | disclosed |
| US-8372981-B2 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-02-12 | — | — | US | disclosed |
| US-7973160-B2 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-7973160-B2 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-7253286-B2 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI CO., LTD (JP) | 2007-08-07 | — | — | US | disclosed |
| EP-1777218-A1 | Process for the preparation of 4-phenoxy quinoline derivatives | Eisai R&D Management Co., Ltd. (JP) | 2007-04-25 | — | — | EP | disclosed |
| EP-1777218-A1 | Process for the preparation of 4-phenoxy quinoline derivatives | Eisai R&D Management Co., Ltd. (JP) | 2007-04-25 | — | — | EP | disclosed |
| CN-1308310-C | Nitrogen-containing aromatic ring derivatives | EISAI CO LTD (JP) | 2007-04-04 | — | — | CN | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-20060247259-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-11-02 | — | — | US | disclosed |
| US-20060160832-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1506962-A2 | Nitrogen-containing aromatic heterocycles | Eisai Co. Ltd. (JP) | 2005-02-16 | — | — | EP | disclosed |
| EP-1415987-A1 | NITROGENOUS AROMATIC RING COMPOUNDS | Eisai Co., Ltd. (JP) | 2004-05-06 | — | — | EP | disclosed |
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | VEGFA, UACA, UTS2R | TTBK1 3557/4885TTBK2 3471/4885KDR 22/4885 |
| US-20060247259-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | UGGT1, FLT1, GCG | TTBK1 2725/4885TTBK2 2703/4885KDR 60/4885 |
| US-20060160832-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | UGGT1, FLT1, GCG | TTBK1 2725/4885TTBK2 2703/4885KDR 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.